Guardant Health disclosed an acquisition of early‑cancer detection startup MetaSight Diagnostics and issued guidance expecting material growth in its Shield colorectal‑cancer screening business for 2026. The MetaSight deal carries $59 million upfront and up to $90 million in contingent consideration tied to commercial and regulatory milestones. Shield, an FDA‑cleared blood test for colorectal cancer, drove Guardant’s management to project sequential quarterly volume increases and screening revenue of $162–$174 million for 2026. Executives cited growing uptake from primary care and partnerships (including integration with Quest Diagnostics) as drivers. The move signals Guardant’s strategy to scale population screening through inorganic additions while commercializing its existing MCED-like products.